13G Filing: Broadfin Capital and Regulus Therapeutics Inc. (RGLS)

Page 5 of 10

Page 5 of 10 – SEC Filing

CUSIP No
75915K101
Item 1.
(a).
Name of Issuer:
Regulus Therapeutics Inc.
(b).
Address of Issuer’s Principal Executive Offices:
10614 Science Center Drive
San Diego, CA 92121
Item 2.
(a).
Name of Person Filing:
Broadfin Capital, LLC
Broadfin Healthcare Master Fund, Ltd.
Kevin Kotler
(b).
Address of Principal Business Office, or if None, Residence:
Broadfin Capital, LLC
300 Park Avenue, 25th Floor
New York, New York 10022
United States of America
Broadfin Healthcare Master Fund, Ltd.
20 Genesis Close
Ansbacher House, Second Floor
P.O. Box 1344
Grand Cayman KY1-1108
Cayman Islands
Kevin Kotler
c/o Broadfin Capital, LLC
300 Park Avenue, 25th Floor
New York, New York 10022
United States of America
(c)
Citizenship:
Broadfin Capital, LLC – Delaware
Broadfin Healthcare Master Fund, Ltd. – Cayman Islands
Kevin Kotler – United States of America
(d).
Title of Class of Securities:
Common Stock, par value $0.001 per share
(e).
CUSIP Number:
75915K101

Follow Regulus Therapeutics Inc. (NASDAQ:RGLS)

Page 5 of 10